Corcept Therapeutics recently announced the initiation of a clinical trial – called Momentum – to examining the prevalence of endogenous hypercortisolism (Cushing’s syndrome) in patients with resistant hypertension.
The trial will enroll 1,000 patients across 45 sites across the U.S. and aims to provide a greater understanding of hypercortisolism as a potential underlying issue for patients living with resistant hypertension. More can be found in a press release here.
MOMENTUM’s design is similar to another recent study – CATALYST clinical trial – which demonstrated that one in four patients with difficult-to-control type 2 diabetes has hypercortisolism. The trial results also showed that hypercortisolism was even more common in patients who also had cardiovascular disease, particularly in those who needed three or more medications to manage their hypertension.
Pituitary World News cofounder Dr. Lewis Blevins notes that it is generally accepted that about 10% of patients with hypertension have a secondary cause due to some other condition. In comparison, 90% have what is referred to as essential hypertension, which is truly multifactorial and has other causes. This study should define the proportion of patients with resistant hypertension who should undergo further study to determine the need for additional treatments directed at an underlying cause.
To find out more about the clinical trial visit clinicaltrials.gov or click here.
© 2025, J D Faccinetti. All rights reserved.